Professor Hextan Y.S. NGAN 顏婉嫦教授

Professor Hextan Y.S. NGAN hku_logo qmh_logo

Chair Professor (Part-time)

MBBS, MD(HK), FRCOG, FHKCOG, FHKAM (O&G); Cert RCOG (Gynae Onc); Accredited gynaecological oncologist (UK and HK); Accredited colposcopist (HKCOG/HKSCCP, HK)
location Department of O&G, Queen Mary Hospital
phone (852)-2255-4517
fax (852)-2855-0947
email HKU Scholars Hub
email https://orcid.org/0000-0003-3945-159X
Research Interests

My research interests include basic, clinical and translational cancer research in gynaecology oncology. My basic research interests have focus on the characterization of putative oncogenes and tumor suppressor genes, as well as their associated signaling pathways involved in the pathogenesis of ovarian, endometrial and cervical carcinomas. Our research team was the first to identify p73alpha is involved in enhancement of the radiosensitive in cervical cancer cells through with the upregulation of p21. Importantly, our team has recently found that the breast cancer–associated gene 3 (BCA3) acts as a novel protein interacting partner of TAp73 and potentiates TAp73 in mediating γ-irradiation–induced apoptosis. These studies reveal the significance of p73 in the radiosensitivity of cervical cancer cells. Moreover, my group has recently reported an important oncogenic transcriptional factor, FOXM1, is frequently overexpressed in cervical and ovarian cancers, and is significantly correlated with the progression and aggressiveness of these cancers. The inhibitory targeting of FOXM1 by RNAi, specific inhibitor e.g. thiostrepton, or even AMPK activators such as metformin could remarkably abrogate the oncogenic capacities of these cancer cells. Ovarian cancer is a relatively poor survival rate disease because of chemoresistance and high rate in tumor recurrence. Hence, our team is particularly interested in the delineation of the underlying mechanisms associated with tumorigenesis and chemoresistance of this disease. Recent studies in our team has not only identified the oncogenic role of FOXM1 in ovarian cancer, they also have found the signaling adaptors, GRB7 and its variant GRB7v, are aberrantly upregulated and associated with a variety of oncogenic capacities by modulating differential signaling pathways. These findings may shed the light of exploring potential therapeutic interventions through targeting these genes. Future studies will include the study of the impacts of tumor microenvironment and cancer cell metabolism on these key pathways involved in the aggressiveness and chemoresistance of ovarian cancer.

My clinical translational research effort have focused on cervical cancer screening especially on the role of HPV testing as well as on psychosocial studies including quality of life. In addition, the identification of new molecular markers in addition to routine HPV screening test is another area of my interested research. Currently my group is conducting a study to compare different HPV test. Lastly, our team has also taken part in contract clinical trials mainly in ovarian cancer treatment and HPV vaccines.


  • Gynaecological oncology – basic and clinical research including HPV, oncogenes, tumour suppressor genes, epigenetic studies and drug trials
  • Cervical cancer screening – basic and clinical research including HPV, cytology, colposcopy studies
  • Psychosocial studies – quality of life, psychosocial and psychosexual studies
PubMed Search

Author Name: Ngan HY

Publications
2024
2023
2022
  • El Helali A., Wong H.L.C., Choi C.W., Chan W.L.W., Dickson N., Siu W.K.S., Chan K.K.L., Ngan H.Y.S., Ngan K.C.R. and Kennedy R.D., A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer, Scientific Reports. 2022, 12.
  • Ngu S.F., Chai Y.K.V., Choi K.M.C., Leung T.W., Li J., Kwok S.T.G., Chu M.Y.M., Tse K.Y., Cheung V.Y.T., Ngan H.Y.S. and Chan K.K.L., Diagnostic Performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and Expert Ultrasound Assessment in a Pelvic Mass Classified as Inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules., Cancers (Basel). . 2022, 14(3), 810.
  • Kwong A., Ho C.Y.S., Shin V.Y., Au C.H., Luk W.P., Fung L.H., Chan T.L., Chan K.K.L., Ngan H.Y.S. and Ma E.S.K., Germline mutations in Chinese ovarian cancer with or without breast cancer, Molecular Genetics & Genomic Medicine. 2022, Epub on 2022-05-24.
  • Ngu S.F., Lau S.K., Li J., Wong C.Y.G., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., Human Papillomavirus Self-Sampling for Primary Cervical Cancer Screening in Under-Screened Women in Hong Kong during the COVID-19 Pandemic., Int J Environ Res Public Health.. 2022, 19(5), 2610.
  • JIANG Y., Siu K.Y., WANG J., Leung T.H.Y., Chan D.W., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-κB Signaling Pathway in Ovarian Cancer, Frontiers in Oncology. 2022, 12.
  • XUAN Y., WANG H., Yung M.H., Chen F., Chan W.S., Chan Y.S., Tsui S.K.W., Ngan H.Y.S., Chan K.K.L. and Chan D.W., SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells, Theranostics. 2022, 12, 3534-3552.
  • Chan K.K.L., Chai Y.K.V., Cheung V.Y.T., Choi K.M.C., Chu M.Y.M., Siu K.Y., Tse K.Y. and Ngan H.Y.S., Use of ultrasonographic rules and tumour marker HE4 level to predict malignancy of a pelvic mass: abridged secondary publication, Hong Kong Med J. 2022
  • Lok Y.W.K., Fan S.L., Ko W.T., Kwok Y.Y., Wong J.Y.H., Fong D.Y.T., Shek W.M.N., Ngan H.Y.S. and Choi P.H., Validating the use of the revised childbirth experience questionnaire in Hong Kong, BMC Pregnancy and Childbirth. 2022, 22.
  • Chen W.C., Ngan H.Y.S., Yang L.Y., Chang W.Y., Wu R.C., Chen C.Y., Lin H., Cheng Y.M., Kan Y.Y., Tseng C.J., Chang C.C., Jung S.M., Tung H.J., Tang Y.H., Lin C.T., Chao A. and Lai C.H., Verification of HPV16 as a good prognostic factor for cervical adeno-adenosquamous carcinoma via an international collaborative study, Taiwanese Journal of Obstetrics and Gynecology. 2022, 61, 494-500
2021
  • WANG J., Siu K.Y., JIANG Y., Leung T.H.Y., Chan D.W., WANG H., Ngan H.Y.S. and Chan K.K.L., A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer, Biomolecules. 2021, 11, 1749. http://dx.doi.org/10.3390/biom11121749
  • HE J., Siu K.Y., Ngan H.Y.S. and Chan K.K.L., Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets, Frontiers in Oncology. 2021, 11. http://dx.doi.org/10.3389/fonc.2021.738177
  • Wong J.Y.H., ZHANG W., Wu Y., Choi P.H., Lo H.H.M., Wong W., Chio J.H.M., Tam H.L.C., Ngai F.W., Tarrant A.M., Wang M.P., Ngan H.Y.S. and Fong D.Y.T., An Interactive Web-Based Sexual Health Literacy Program for Safe Sex Practice for Female Chinese University Students: Multicenter Randomized Controlled Trial, Journal of Medical Internet Research. 2021, 23, e22564. http://dx.doi.org/10.2196/22564
  • Fan S.L., Choi P.H., Ko W.T., Kwok Y.Y., Wong J.Y.H., Fong D.Y.T., Shek W.M.N., Ngan H.Y.S., Li J., H Y.Y., O Y.Q. and Lok Y.W.K., Covid‐19 Related Fear And Depression Of Pregnant Women And New Mothers, Public Health Nursing. 2021. http://dx.doi.org/10.1111/phn.13035
  • Tse K.Y., Wong R.W.C., Chao A., Ueng S.H., Yang L.Y., Cummings M., Smith D., Lai C.R., Lau H.Y., Yen M.S., Cheung A.N.Y., Leung C.K.L., Chan K.S., Chan A.N.H., Li W.H., Choi K.M.C., Pong W.M., Hui H.F., Yuk J.Y.W., Yao H., Yuen N.W.F., Obermair A., Lai C.H., Ip P.C.P. and Ngan H.Y.S., Development of a Multi-Institutional Prediction Model for Three-Year Survival Status in Patients with Uterine Leiomyosarcoma (AGOG11-022/QCGC1302 Study)
  • WANG X., Yung M.H., Sharma R., Chen F., Poon Y.T., Lam W.Y., Li B., Ngan H.Y.S., Chan K.K.L. and Chan D.W., Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-κB Axis, Cancers. 2021, 13, 4795. http://dx.doi.org/10.3390/cancers13194795
  • Chan D.W., Lam W.Y., Chen F., Yung M.H., Chan Y.S., Chan W.S., He F., Liu S., Chan K.K.L., Li B. and Ngan H.Y.S., Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers, Clinical Epigenetics. 2021, 13. http://dx.doi.org/10.1186/s13148-021-01130-5
  • Kwong A., Shin V.Y., Ho Y.S.C., Khalid A., Au C.H., Chan K.K.L., Ngan H.Y.S., Chan T.L. and Ma E.S.K., Germline PALB2 mutation in high-risk Chinese breast and/or ovarian cancer patients, Cancers. 2021, Epub on 2021-08-20. http://dx.doi.org/10.3390/cancers13164195
  • WAN K.T., Leung T.H.Y., Siu K.Y., MO X., Tang W.M., Chan K.K.L., Cheung A.N.Y. and Ngan H.Y.S., HPV-induced Nurr1 promotes cancer aggressiveness, self-renewal, and radioresistance via ERK and AKT signaling in cervical cancer, Cancer Letters. 2021, 497, 14-27. http://dx.doi.org/10.1016/j.canlet.2020.09.025
  • Yung S.F.S., Lai S.F., Lam M.T., Lui M.W.E., Ko K.Y.J., Li R.H.W., Wong J.Y.Y., Lau Y.L.E., Yeung W.S.B. and Ng E.H.Y., Hyaluronic acid–enriched transfer medium for frozen embryo transfer: a randomized, double-blind, controlled trial, Fertility and Sterility. 2021, 116, 1001-1009. http://dx.doi.org/10.1016/j.fertnstert.2021.02.015
  • Lok Y.W.K., Ko W.T., Fan S.L., Wong J.Y.H., Choi P.H., Shek W.M.N., Ngan H.Y.S., Tarrant A.M., Li J., Huang Y.Y., Ouyang Y.Q. and Fong D.Y.T., International survey on fear and childbirth experience in pregnancy and the postpartum period during the COVID-19 pandemic: study protocol, BMJ Open. 2021, 11, e050132. http://dx.doi.org/10.1136/bmjopen-2021-050132
  • Han C., Patten D., Kim S., Lim J., Chan D.W., Siu K.Y., Han Y., Carmona E., Parks R., Lee C., Di L.J., Lu Z., Chan K.K.L., Ku J.L., Macdonald E., Vanderhyden B., Mes-Masson A.M., Ngan H.Y.S., Cheung A.N.Y., Song Y., Bast R., Harper M.E. and Tsang B., Nuclear HKII–P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer, Cancers. 2021, 13, 3399. http://dx.doi.org/10.3390/cancers13143399
  • Ngu S.F., Tse K.Y., Chu M.Y.M., Ngan H.Y.S. and Chan K.K.L., Olaparib dose re-escalation in ovarian cancer patients who experienced severe and/or uncommon adverse events: A case series., Asia Pac J Clin Oncol.. 2021, 17, 3-11. http://dx.doi.org/10.1111/ajco.13584
  • WANG M., Perucho J.A.U., Vardhanabhuti V., Ip P.C.P., Ngan H.Y.S. and Lee E.Y.P., Radiomic Features of T2-weighted Imaging and Diffusion Kurtosis Imaging in Differentiating Clinicopathological Characteristics of Cervical Carcinoma, Academic Radiology. 2021. http://dx.doi.org/10.1016/j.acra.2021.08.018
  • Chan K.K.L., Yeung C.K., Lam K.W., Cheung J.L.K., Sreedhar B. and Ngan H.Y.S., Robotic Natural Orifice Transluminal Endoscopic Surgery Hysterectomy and Salpingo-Oophorectomy in a Porcine Model, Surgical Innovation. 2021, 155335062110184. http://dx.doi.org/10.1177/15533506211018433
  • Ngu S.F., Ngan H.Y.S. and Chan K.K.L., Role of adjuvant and post-surgical treatment in gynaecological cancer, Best Practice & Research Clinical Obstetrics & Gynaecology. 2021. http://dx.doi.org/10.1016/j.bpobgyn.2021.09.001
  • Li J., Wu R., Yung M.H., Sun J., Li Z., Yang H., Zhang Y., Liu S., Cheung A.N.Y., Ngan H.Y.S., Braisted J.C., Zheng W., Wei H., Gao Y., Nemes P., Pei H., Chan D.W., Li Y. and Zhu W., SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance, Cell Death & Disease. 2021, 12. http://dx.doi.org/10.1038/s41419-021-03635-6
  • WANG H., Yung M.H., Ngan H.Y.S., Chan K.K.L. and Chan D.W., The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression, International Journal of Molecular Sciences. 2021, 22, 6560. http://dx.doi.org/10.3390/ijms22126560
  • LIANG R., Yung M.H., He F., JIAO P., Chan K.K.L., Ngan H.Y.S. and Chan D.W., The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment, Cancers. 2021, 13, 4577. http://dx.doi.org/10.3390/cancers13184577
2020
  • An H., Chiu K.W.H., Tse K.Y., Ngan H.Y.S., Khong P.L. and Lee E.Y.P., The value of contrast-enhanced CT in the detection of residual disease after neo-adjuvant chemotherapy in ovarian cancer, Acad Radiol. 2020 Jul;27(7):951-957. doi: 10.1016/j.acra.2019.09.019. Epub 2019 Oct 16.
  • Siu K.Y., JIANG Y., WANG J., Leung T.H.Y., Ngu S.F., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via α5β1 integrin and JNK/IL-8 signaling, Oncogenesis. 2020, 9. http://dx.doi.org/10.1038/s41389-020-0209-0
  • Chan K.K.L., Liu S., Wei N., Ngu S.F., Chu M.Y.M., Tse K.Y., Lau S.K., Cheung A.N.Y. and Ngan H.Y.S., Primary HPV testing with cytology versus cytology alone in cervical screening—A prospective randomized controlled trial with two rounds of screening in a Chinese population , International Journal of Cancer. 2020. http://dx.doi.org/10.1002/ijc.32861
2019

  • CHEN R., Yung M.H., XUAN Y., ZHAN S., LEUNG L.L., LIANG R., Leung T.H.Y., Yang H.J., Xu D., Sharma R., Chan K.K.L., Ngu S.F., Ngan H.Y.S. and Chan D.W., Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells, Communications Biology. 2019, 2. http://dx.doi.org/10.1038/s42003-019-0508-1

  • Guevara A.M., Suarez E., Victoria A., Ngan H.Y.S., Hirschberg A.L., Fedrizzi E., Bautista O., Shields C., Joshi A. and Luxembourg A., Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine, Hum Vaccin Immunother, 2019, 2019, 15(1), 141-145. http://dx.doi.org/10.1080/21645515.2018.1514227

  • Leung T.H.Y., Tang W.M., Siu K.Y., Chan D.W., Chan K.K.L., Cheung A.N.Y. and Ngan H.Y.S., CD71(+) population enriched by HPV-E6 protein promotes cancer aggressiveness and radioresistance in cervical cancer cells, Molecular Cancer Research. 2019, molcanres.0068.2019. http://dx.doi.org/10.1158/1541-7786.MCR-19-0068

  • Li Z., Zhou W., Zhang Y., Sun W., Yung M.H., Sun J., Li J., Chen C.W., Li Z., Meng Y., Chai J., Zhou Y., Liu S., Cheung A.N.Y., Ngan H.Y.S., Chan D.W., Zheng W. and Zhu W., ERK regulates HIF-1α-mediated platinum resistance by directly targeting PHD2 in ovarian cancer, Clinical Cancer Research. 2019, clincanres.4145.2018. http://dx.doi.org/10.1158/1078-0432.CCR-18-4145

  • Ngan H.Y.S., Seckl M.J., Berkowitz R.S., Xiang Y., Golfier F., Sekharan P.K., Lurain J.R. and Massuger L., Update on the diagnosis and management of gestational trophoblastic disease, Int J Gynaecol Obstet. 2018 Oct, 2019, 143 Suppl 2, 79-85. http://dx.doi.org/10.1002/ijgo.12615

  • Siu K.Y., JIANG Y., WANG J., Han C.Y., Tsang B.K., Cheung A.N.Y., Ngan H.Y.S. and Chan K.K.L., Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades , Cancers. 2019, 11( 6 ), 813. http://dx.doi.org/10.3390/cancers11060813

  • Sun J., Cai X., Yung M.H., Zhou W., Li J., Zhang Y., Li Z., Liu S., Cheung A.N.Y., Ngan H.Y.S., Li Y., Dai Z., Kai Y., Tzatsos A., Peng W., Chan D.W. and Zhu W., miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer, Oncogene. 2019, 38, 564-580. http://dx.doi.org/10.1038/s41388-018-0459-x

  • YU Y., Tse K.Y., Lee H.Y.H., Chow K.L., Tsang H.W., Wong W.C., CHEUNG E.T.Y., CHEUK W., LEE V.W.K., CHAN W.K., Wong A.S.T., LOONG H.H.F., Chan K.K.L., Ngan H.Y.S., Cheung A.N.Y. and Ip P.C.P., Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases, Modern Pathology. 2019. http://dx.doi.org/10.1038/s41379-019-0345-2

2018

  • Chan K.K.L., Siu K.Y., JIANG Y., WANG J., Leung T.H.Y. and Ngan H.Y.S., Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer., Cancer Cell Int.. 2018, 18. http://dx.doi.org/10.1186/s12935-018-0559-2 (Publication No. : 290709)

  • CHEN K., Liu X., MAK S.L., Yung M.H., Leung T.H.Y., Xu D., Ngu S.F., Chan K.K.L., Yang H.J., Ngan H.Y.S. and Chan D.W., Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness by targeting GRB7 and MAPK/ERK pathways , Theranostics. 2018, 8: 423-436. http://dx.doi.org/10.7150/thno.22377 (Publication No. : 284013)

  • Garland S.M., Pitisuttithum P., Ngan H.Y.S., Cho C.H., Lee C.Y., Chen C.A., Yang Y.C., Chu T.Y., Twu N.F., Samakoses R., Takeuchi Y., Cheung T.H., Kim S.C., Huang L.M., Kim B.G., Kim Y.T., Kim K.H., Song Y.S., Lalwani S., Kang J.H., Sakamoto M., Ryu H.S., Bhatla N., Yoshikawa H., Ellison M.C., Han S.R., Moeller E., Murata S., Ritter M., Sawata M., Shields C., Walia A., Perez G. and Luxembourg A., Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries, J Infect Dis. 2018, 218(1): 95-108. http://dx.doi.org/10.1093/infdis/jiy133 (Publication No. : 286311)

  • Kwong A., HO C.W.J., Shin V.Y., Kurian A.W., Tai E., Esserman L.J., Weizel J.N., Lin P.H., Field M., Domcheck S.M., Ngan H.Y.S., Ma E.S.K., Chan T.L. and Ford J.M., Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels, Oncotarget. 2018, 9(8): 7832-7843. http://dx.doi.org/10.18632/oncotarget.23471 (Publication No. : 284559)

  • Lam W.L., Yeung W.F., Wong M.K., Cheung C.W., Chan K.K.L., Ngan H.Y.S., Wong C.K.H., Chen H. and Lao L., Combined electroacupuncture and auricular acupuncture for postoperative pain after abdominal surgery for gynecological diseases: study protocol for a randomized controlled trial, Trials. 2018, 19: 8. http://dx.doi.org/10.1186/s13063-017-2359-8 (Publication No. : 284026)

  • LEUNG L.L., Yung M.H., Ngan H.Y.S. and Chan D.W., Study of hedgehog signaling in cervical cancer, ESMO Open. BMJ, 2018, 3: A89-A89. http://dx.doi.org/10.1136/esmoopen-2018-EACR25.214 (Publication No. : 295865)

  • Liu S., Chan K.K.L., Chu K.H., Wei N., Lau S.K., Ngu S.F., Chu M.Y.M., Tse K.Y., Ip P.C.P., Ng E.K.O., Cheung A.N.Y. and Ngan H.Y.S., Oncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer, 2018. http://dx.doi.org/10.1002/1878-0261.12383(Publication No. : 294143)

  • Mak C.M., Law E.C., Lee H.H., Siu W.K., Chow K.M., Au Yeung S.K., Ngan H.Y.S., Tse N.K., Kwong N.S., Chan G.C., Lee K.W., Chan W.P., Wong S.F., Tang M.H., Kan A.S., Hui A.P., So P.L., Shek C.C., Lee R.S., Wong K.Y., Yau E.K., Poon K.H., Siu S., Poon G.W., Kwok A.M., Ng J.W., YimV.C., Ma G.G., Chu C.H., Tong T.Y., Chong Y.K., Chen S.P., Ching C.K., Chan A.O., Tam S., Lau R.L., Ng W.F., Lee K.C., Chan A.Y. and Lam C.W., The first pilot study of expanded newborn screening for inborn errors of metabolism and survey of related knowledge and opinions of health care professionals in Hong Kong, Hong Kong Med J. 2018, 24(3): 226-237. http://dx.doi.org/10.12809/hkmj176939 (Publication No. : 286310)

  • Meng Y., Chen C.W., Yung M.H., Sun W., Sun J., Li Z., Li J., Li Z., Zhou W., Liu S., Cheung A.N.Y., Ngan H.Y.S., Braisted J.C., Kai Y., Peng W., Tzatsos A., Li Y., Dai Z., Zheng W., Chan D.W. and Zhu W., DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer, Cancer Letters. 2018. http://dx.doi.org/10.1016/j.canlet.2018.04.029 (Publication No. : 285074)

  • Ngu S.F., Chu M.Y.M., Tse K.Y., Chan K.K.L., Ip P.C.P., Cheung A.N.Y. and Ngan H.Y.S., Role Of Lymphadenectomy And Vincristine, Actinomycin-D, and Cyclophosphamide Chemotherapy in Malignant Ovarian Germ Cell Tumors, European Journal of Gynaecological Oncology. 2018, 39(1): 63-69. http://dx.doi.org/10.12892/ejgo3763.2018 (Publication No. : 284270)

  • Sun J., Cai X., Yung M.H., Zhou W., Li J., Zhang Y., Li Z., Liu S., Cheung A.N.Y., Ngan H.Y.S., Li Y., Dai Z., Kai Y., Tzatsos A., Peng W., Chan D.W. and Zhu W., miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer, Oncogene. Springer Nature Limited, 2018. http://dx.doi.org/10.1038/s41388-018-0459-x (Publication No. : 290017)

  • Tang K.S., Yue P.Y.K., Ip P.C.P., Huang R.L., Lai H.C., Cheung A.N.Y., Tse K.Y., Ngan H.Y.S. and Wong A.S.T., Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface, Nature Communications. 2018, 9: 2270. http://dx.doi.org/10.1038/s41467-018-04695-7 (Publication No. : 285801)

  • Tse K.Y., Chiu W.H.K., Chan K.K.L., Chu M.Y.M., Ngu S.F., Cheung A.N.Y., Ngan H.Y.S. and Ip P.C.P., A Case Series of Five Patients With Pure or Mixed Gestational Epithelioid Trophoblastic Tumors and a Literature Review on Mixed Tumors, American Journal of Clinical Pathology. 2018. http://dx.doi.org/10.1093/ajcp/aqy039 (Publication No. : 285802)

  • Wong G.W., Cheung L.Y., Ip P.C.P., Ngan H.Y.S. and Cheung A.N.Y., Amyloid Precursor Protein Overexpression in Down Syndrome Trophoblast Reduces Cell Invasiveness and Interferes with Syncytialization, The Amercian Journal of Pathology. 2018, 188(10): 2307-17. (Publication No. : 294138)

  • Xiang L., Jiang W., Ye S., He T., Pei X., Li J., Chan D.W., Ngan H.Y.S., Li F., Tao P., Shen X., Zhou X., Wu X., Yang G. and Yang H., ERBB2 mutation: A promising target in non-squamous cervical cancer, Gynecologic Oncology. 2018. http://dx.doi.org/10.1016/j.ygyno.2017.12.023(Publication No. : 284014)

  • Yung M.H., Tang W.M., Cai C.H., Leung T.H.Y., Ngu S.F., Chan K.K.L., Xu D., Yang H.U.I.J.U.A.N., Ngan H.Y.S. and Chan D.W., GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade, Theranostics. 2018, 8: 1270-1285. http://dx.doi.org/10.7150/thno.22536 (Publication No. : 284377)

  • Zhou W., Sun W., Yung M.H., Dai S., Cai Y., Chen C.W., Meng Y., Lee J.B., Braisted J.C., Xu Y., Southall N.T., Shinn P., Huang X., Song Z., Chen X., Kai Y., Cai X., Li Z., Hao Q., Cheung A.N.Y., Ngan H.Y.S., Liu S., Barak S., Hao J., Dai Z., Tzatsos A., Peng W., Pei H., Han Z., Chan D.W., Zheng W. and Zhu W., Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance, Oncogene. 2018. http://dx.doi.org/10.1038/s41388-018-0238-8 (Publication No. : 284933)

2017

  • Chan D.W., Hui W.W., Wang J.J., Yung M.H., Hui M.N., Qin Y.I.M.I.N.G., LIANG R., Leung T.H.Y., Xu D., Chan K.K.L., Yao K.M., Tsang B.K. and Ngan HYS, DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling, Oncogene. 2017 Mar;36(10):1404-1416.

  • Chan D.Y.L., Lam K.K.W., Lau E.Y.L, Yeung W.S.B., Ng E.H.Y., Human varicella zoster virus is not present in the semen of a man affected by chickenpox during the in vitro fertilisation of his wife. Andrologia. 2017 Jul 3. doi: 10.1111/and.12822.

  • Chan K.K.L., Siu K.Y., JIANG Y., WANG J., Wang Y., Leung T.H.Y., Liu S., Cheung A.N.Y. and Ngan H.Y.S., Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis, BMC Cancer. 2017.

  • CHEN K., Ngan H.Y.S. and Chan D.W., Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness via targeting GRB7, Cancer Research. 2017, 77: LB-324-LB-324.

  • KL Chow, KY Tse, CL Cheung, KW Wong, ANY Cheung, RWC Wong, ANH Chan, NWF Yuen, HYS Ngan, PPC Ip. The mitosis-specific marker phosphohistone-H3 (PHH3) is an independent prognosticator in uterine smooth muscle tumors: an outcome-based study. Histopathology 2017; 70: 746 - 55

  • Kwong A., Ho J.C.W., Shin V.Y., Kurian A.W., Tai E., Esserman L.J., Weitzel J.N., Lin P.H., Field M., Domchek S.M., Lo J., Ngan H.Y.S., Ma E.S.K., Chan T.L., Ford J.M., Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels, Oncotarget, 2017 Dec 20;9(8):7832-7843

  • KY Tse, HYS Ngan, PC Lim. Robot-assisted gynaecological cancer surgery – complications and prevention. Best Pract Res Clin Obstet Gynaecol 2017 Apr 23. pii: S1521-6934(17)30063-9. doi: 10.1016/j.bpobgyn.2017.04.005. [Epub ahead of print]

  • Leung THY, Tang HWM, Siu MKE, Chan DW, Chan KKL, Cheung ANY and Ngan HY. HPV-E6 protein enriches the CD55(+) population in cervical cancer cells promoting radio-resistance and cancer aggressiveness. J. Pathol. 2017 244(2):151-163.

  • Mak CS, Yung MM, Hui LM, Leung LL, Liang R, Chen K, Liu SS, Qin Y, Leung TH, Lee KF, Chan KK, Ngan HY, Chan DW. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. Mol Cancer. 2017 Jan 17;16(1):11. doi: 10.1186/s12943-017-0582-2.

  • Mak CS, Yung MMH, Hui LMN, Leung LL, Liang R, Chen KM, Liu SS, Qin Y, Leung THY,  Lee KF, Chan KKL, Ngan HYS and Chan DW*  Dysregulation of miR-141/KLF12/Sp1/survivin signaling promotes anoikis resistance in ovarian cancer metastatic progression. Mol Cancer 2017 16(1):1-17.

  • Ngu SF, Chu MM, Ip PP, Ngan HY. Vulvar Hidradenitis Suppurativa: Is the Mass Malignant? J Obstet Gynaecol Can. 2017 Mar 30. S1701-2163(16)39741-9.

  • Ngu SF, Wei N, Kwan TT, Chu MM, Tse KY, Chan KK, Ngan HY. Impact of different educational interventions on psychosocial well-being of women with a positive high-risk human papillomavirus and normal cervical cytology: a randomised trial. J Psychosom Obstet Gynaecol. 2017 Apr 10:1-10.

  • SF Ngu, N Wei, TTC Kwan, MMY Chu, KY Tse, KKL Chan, HYS Ngan. Impact of different educational interventions on psychosocial wellbeing of Hong Kong Chinese women with a positive high-risk human papillomavirus and normal cervical cytology. Journal of Psychosomatic Obstetrics & Gynecology 2017: 10: 1 – 10.

  • Wong J.H., Sze S.C.W., Ng T.B., Cheung R.C.F., Tam C., Zhang K.Y., Dan X., Chan Y.S., Cho W.C.S., Ng C.C.W., Waye M.M.Y., Liang W., Zhang J., Yang J., Ye X., Lin J., Ye X.J., Wang H., Liu F., Chan D.W., Ngan H.Y.S., Sha O., Li G., Tse R., Tse T.K. and Chan H., Apoptosis and anti-cancer drug discovery: the power of medicinal fungi and plants, In: Atta-ur-Rahman, FRS, Current Medicinal Chemistry. Bentham Science, 2017, 24: E-pub Abstract Ahead of Print.

2016

  • Chan D.W., Hui W.W., Wang J.J., Yung M.H., Hui M.N., Qin Y.I.M.I.N.G., LIANG R., Leung T.H.Y., Xu D., Chan K.K.L., Yao K.M., Tsang B.K. and Ngan H.Y.S., DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling, In: Drs. Douglas Green and Justin Stebbing , Oncogene. UK, Macmillan Publishers Limited, 2016, 36: 1404-1416.

  • CHEN R., Ngan H.Y.S. and Chan D.W., The roles of AMPK and TAK1/NF-kB signaling cascade in governing cancer cell aggressiveness in omental microenvironemnt, European Journal of Cancer. 2016, 61: S165-S166

  • Chu MM, Tse KY, Chan KK, Cheung AN, Ngan HY. Placental site trophoblastic tumour – a distinct entity of gestational trophoblastic disease: experience from a tertiary referral center in Hong Kong. J Reprod Med. 2016 Aug;61(4):351-6

  • KY Tse, SK Lau, MW Lui, PPC Ip, ANY Cheung, HYS Ngan. Patient compliance with cervical smear surveillance in a shared-care setting. Int J Gyn Obs 2016; 135: 177 - 81

  • KY Tse, VYT Cheung, C Lam, EYP Lee, PL Khong, HYS Ngan. Successful treatment of a para-renal pregnancy using high-dose methotrexate regimen. J Reprod Med 2016; 61: 592 – 94

  • Su H., Tiwari A.F.Y., Ngan H.Y.S., Yip Y.L., Cheung A., Tsao G.S.W. and Deng W., Extremely stringent activation of p16INK4a prevents immortalization of uterine cervical epithelial cells without human papillomavirus oncogene expression, Oncotarget. 2016, 7(29): 45656-45670.

  • Yung MH, Ngan HYS and Chan DW*.  Targeting AMPK signaling in combating ovarian cancers: Opportunities and Challenges. Acta Biochimica et Biophysica Sinica. 2016 48(4):301-17.

  • Yung MH, Ross FA, Hardie DG, Leung TH, Zhan JB, Ngan HYSand Chan DW*.  Bitter melon (Momordica charantia) extract functions as a natural AMPK activator and synergistically enhances cisplatin cytotoxicity in ovarian cancer cells. Integrat Cancer Ther. 2016 15(3):376-89. (The most read paper in 2015/16) * (Corresponding author)

2015

  • Chu MM, Ma Y, Tse KY, Chan KK, Ngan HY. Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia. International Journal of Gynecological Cancer 2015 Mar;25(3):498-503.

  • Chu MYM, Liu S, Tam KF, Ip PCP, Cheung ANY and Ngan HYS. The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer. Int J Gynecol Pathology 2015, 34: 403-410.

  • Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A, Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer 2015 Nov 19.

  • KY Tse, KKL Chan, KF Tam, HYS Ngan. Current management of gestational trophoblastic disease. Obstetrics, Gynaecology & Reproductive Medicine 2015; 25 (1): 12 – 21

  • Leung TW, Liu S, Leung CY, Chu MM, Cheung ANY and Ngan HYS. HPV 16 E2 binding sites 1 and 2 become more methylated than E2 binding site 4 during cervical carcinogenesis. J Med Virol 2015, 2015 Jun;87(6):1022-33.

  • Mak VC, Wong OG, Siu MK, Wong ES, Ng WY, Wong RW, Chan KK, Ngan HY, Cheung AN. FBI-1 Is Overexpressed in Gestational Trophoblastic Disease and Promotes Tumor Growth and Cell Aggressiveness of Choriocarcinoma via PI3K/Akt Signaling. Am J Pathol 2015 Jul;185(7):2038-48.

  • Ngan HY, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR, Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet 2015 Oct;131 Suppl 2:S123-6.

  • Ngu SF and Ngan HYS. Chemotherapy in pregnancy. Best Pract Res Clin Obstet Gynaecol 2015, http://dx.doi.org/10.1016/j.bpobgyn.2015.10.007

  • Park JY, Ngan HY, Park W, Cao Z, Wu X, Ju W, Chung HH, Chang SJ, Park SY, Ryu SY, Kim JH, Cho CH, Lee KH, Lee JW, Kumarasamy S, Kim JW, Wilailak S, Kim BG, Kim DY, Konishi I, Lee JK, Wang KL, Nam JH. Asian Society of Gynecologic Oncology International Workshop 2014. J Gynecol Oncol 2015 Jan;26(1):68-74.

  • Siu KY, Kong DS, Ngai SY, Chan HY, Jiang L, Wong ESY, Liu S, Chan KKL, Ngan HYS and Cheung ANY. p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation. PLoS One 2015, 10(7): e0133467.

  • Tse KY and Ngan HYS. The role of laparoscopy in staging of different gynaecological cancers. Best Pract Res Clin Obstet Gynaecol 2015, S1521-6934 (15)00030-9.

2014

  • Cai C, Shi L, Liu VWS, Tang WM, Liu J, Leung THY, Chan KKL, Yam JWP, Yao KM, Ngan HYS and Chan DW. Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling. Oncotarget 2014, 5: 7549-62.

  • Cai PC, Shi L, Liu VW, IJ Liu, Leung TH, Chan KK, Yao KM, Ngan HYS* and Chan DW*.  TAK1 promotes ovarian cancer aggressiveness through activation of NF-κB signal pathway. Oncotarget 2014 5(17):7549-62. (* Co-corresponding author)

  • Chan KKL, Leung TH, Chan DW, Wei N, Lau GT, Liu SS, Siu MK, and Ngan HY.  Targeting estrogen receptor subtypes in ovarian cancer. J. Endocrinol2014 221(2):325-36.

  • Chan KKL, Leung THY, Chan DW, Wei N, Lau TY, Liu S, Siu KY and Ngan HYS. Targeting estrogen receptor subtypes (ERalpha and ERbeta) with selective ER modulators in ovarian cancer. Journal of Endocrinology 2014, 221: 325-336.

  • Lee EY, Yu X, Chu MM, Ngan HY, Siu SW, Soong IS, Chan Q, Khong PL. Perfusion and diffusion characteristics of cervical cancer based on intraxovel incoherent motion MR imaging-a pilot study. Eur Radiol. 2014 Jul;24(7):1506-13

  • Leung CO, Deng W, Ye TM, Ngan HYS, Tsao SW, Cheung ANY, Pang RTK and Yeung WSB. miR-135a leads to cervical cancer cell transformation through regulation of β-catenin via a SIAH1-dependent ubiquitin proteosomal pathway. Carcinogenesis 2014 Sep;35(9):1931-40.

  • Li C, Liu VWS, Chiu PM, Yao KM, Ngan HYS and Chan DW. Reduced expression of AMPK-beta1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. Molecular Cancer 2014, 13: 49.

  • Liu MX, Siu MMK, Liu SS, JW Yam and Ngan HYS*and Chan DW*. Epigenetic silencing of miR-199b-5p is associated with chemoresistance of ovarian cancer through activation of JAG-1/NOTCH signaling cascade. Oncotarget 20145(4):94-958. (* co-corresponding author)

  • Liu X, Siu KY, Liu S, Yam JWP, Ngan HYS and Chan DW. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 2014, 5: 944–958.

2013

  • Chan RW, Mak AS, Yeung WS, Lee KF, Cheung AN, Ngan HY, Wong AS. Human female reproductive tract epithelial cell culture. Methods Mol Biol. 2013;945:347-63. [PubMed]

  • Kwan HT, Chan DW, Cai PC, Mak CS, Yung MM, Leung TH, Wong OG, Cheung AN, Ngan HY. AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/β-catenin signaling activity. PLoS One. 2013;8(1):e53597. [PubMed]

  • Lee EY, Khong PL, Tse KY, Chan KK, Chu MM, Ngan HY. Differentiation of aggressive and indolent subtypes of uterine sarcoma using maximum standardized uptake value. Nucl Med Commun. 2013; 34(12):1185-9.

  • Leung TH, Wong SC, Chan KK, Chan DW, Cheung AN, Ngan HY.The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells. Br J Cancer. 2013 Aug 20;109(4):965-75. [PubMed]

  • Mak VC, Lee L, Siu MK, Wong OG, Lu X, Ngan HY, Wong ES, Cheung AN. Downregulation of ASPP2 in choriocarcinoma contributes to increased migratory potential through Src signaling pathway activation. Carcinogenesis. 2013 Jun 17. [Epub ahead of print] [PubMed]

  • Obermair A, Tang A, Kondalsamy-Chennakesavan S, Ngan H, Zusterzeel P, Quinn M, Carter J, Leung Y, Janda M. Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors. Int J Gynecol Cancer. 2013 Feb;23(2):264-7. [PubMed]

  • Siu MK, Wong ES, Kong DS, Chan HY, Jiang LL, Wong OS, Lam EW, Chan KK, Ngan HY, Le XF, Cheung AN. Stem cell transcription factor Nanog promotes ovarian cancer cell migration and invasion through E-cadherin and FOXJ1 and associates with poor prognosis in patients. Oncogene 2013; 32:3500-9. [PubMed]

  • Yung MM, Chan DW, Liu VW, Yao KM, Ngan HY. Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade. BMC Cancer. 2013 Jul 3;13:327. doi: 10.1186/1471-2407-13-327. [PubMed]

2012

  • Chan DW, Hui WY, Cai C, Liu X, Yung MH, Mak SL, Leung THY, Chan KKL, Ngan HYS. Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells. PLoS ONE. 2012, 7: e52578. [PubMed]

  • Chan DW, Mak CS, Leung TH, Chan KK, Ngan HY. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer. Oncotarget. 2012 Dec;3(12):1546-56. [PubMed]

  • Chan DW, Ngan HYS. The potential molecular therapeutic approach in targeting ovarian clear cell carcinoma, Gynecology & Obstetrics. OMICS Group, 2012, 2: 1000e103. 

  • Chan KKL, Kwan TTC, Yao T, Tam KF, Cheung ANY, Ngan HYS. Human papillomavirus vaccine: What are women most concerned about? J Obstet Gynaecol Res. 2012, 38(1): 23-30. 

  • Fung FK, Chan DW, Liu VW, Leung TH, Cheung AN, Ngan HY. Increased expression of PITX2 transcription factor contributes to ovarian cancer progression. PLoS One. 2012;7(5):e37076. [PubMed]

  • Garland SM, Bhatla N, Ngan HY. Cervical cancer burden and prevention strategies: Asia Oceania perspective. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1414-22. 

  • Kondalsamy-Chennakesavan S, Janda M, Gebski V, Baker J, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, Nascimento M, Neesham D, Nicklin JL, Oehler MK, Otton G, Perrin L, Salfinger S, Hammond I, Leung Y, Sykes P, Ngan H, Garrett A, Laney M, Ng TY, Tam K, Chan K, Wrede DH, Pather S, Simcock B, Farrell R, Robertson G, Walker G, McCartney A, Obermair A. Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer. 2012 Sep;48(14):2155-62.

  • Kwan TT, Lo SS, Tam KF, Chan KK, Ngan HY. Assessment of knowledge and stigmatizing attitudes related to human papillomavirus among Hong Kong Chinese healthcare providers. Int J Gynaecol Obstet. 2012 Jan;116(1):52-6. 

  • KY Tse, KKL Chan, KF Tam, HY Ngan. Update on gestastional trophoblastic disease. Obstetrics, Gynaecology & Reproductive Medicine 2012; 22: 7 – 15

  • Li C, Liu VW, Chan DW, Yao KM, Ngan HY. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. Int J Gynecol Cancer. 2012 Jan;22(1):15-22. [PubMed]

  • Li C, Liu VW, Chiu PM, Chan DW, Ngan HY. Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications. BMC Cancer. 2012 Aug 16;12:357. [PubMed]

  • Liu X, Chan DW, Ngan HYS. Mechanisms of Chemoresistance in Human Ovarian Cancer at a Glance. Gynecology & Obstetrics. 2012; 2:1000e104. [PubMed]

  • Mak VC, Siu MK, Wong OG, Chan KK, Ngan HY, Cheung AN. Dysregulated stemness-related genes in gynecological malignancies. Histol Histopathol 2012; 27:1121-30. [PubMed]

  • Ngan HY, Kohorn EI, Cole LA, Kurman RJ, Kim SJ, Lurain JR, Seckl MJ, Sasaki S, Soper JT. Trophoblastic disease. Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S130-6. 

  • Obermair A, Janda M, Baker J, Kondalsamy-Chennakesavan S, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, Nascimento M, Neesham D, Nicklin JL, Oehler MK, Otton G, Perrin L, Salfinger S, Hammond I, Leung Y, Sykes P, Ngan H, Garrett A, Laney M, Ng TY, Tam K, Chan K, Wrede DH, Pather S, Simcock B, Farrell R, Robertson G, Walker G, McCartney A, Gebski V. Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer. 2012 May;48(8):1147-53.

  • Siu MK, Kong DS, Chan HY, Wong ES, Ip PP, Jiang L, Ngan HY, Le XF, Cheung AN. Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS One. 2012;7(11):e47201. [PubMed]

  • Tang A, Kondalsamy-Chennakesavan S, Ngan H, Zusterzeel P, Quinn M, Carter J, Leung Y, Obermair A. Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801). Gynecol Oncol. 2012 Jul;126(1):36-40. [PubMed]

  • Tse KY, Ngan HY. Gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):357-70. [PubMed]

  • Wei N, Liu SS, Chan KK, Ngan HY. Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. PLoS One. 2012;7(1):e30311. [PubMed]

  • Wong OG, Lo CK, Chow JN, Tsun OK, Szeto E, Liu SS, Ngan HY, Cheung AN. Comparison of the GenoFlow human papillomavirus (HPV) test and the Linear Array assay for HPV screening in an Asian population. J Clin Microbiol. 2012 May;50(5):1691-7. [PubMed]

  • Zhang P, Liu SS, Ngan HY. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells. PLoS One. 2012;7(8):e42985. [PubMed]

2011

  • Chan DW, Liu VW, Leung LY, Yao KM, Chan KK, Cheung AN, Ngan HY. Zic2 synergistically enhances Hedgehog signalling through nuclear retention of Gli1 in cervical cancer cells. J Pathol. 2011 Dec;225(4):525-34. [PubMed]

  • Chan KK, Yao TJ, Jones B, Zhao JF, Ma FK, Leung CY, Lau SK, Yip MW, Ngan HY. The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol. 2011 Oct;22(10):2241-9. [PubMed]

  • Cheung LW, Mak AS, Cheung AN, Ngan HY, Leung PC, Wong AS. P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin. Oncogene. 2011 Jun 30;30(26):2964-74.

  • Ip CK, Cheung AN, Ngan HY, Wong AS. p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene. 2011 May 26;30(21):2420-32. 

  • Jiang L, Siu MK, Wong OG, Tam KF, Lu X, Lam EW, Ngan HY, Le XF, Wong ES, Monteiro LJ, Chan HY, Cheung AN. iASPP and Chemoresistance in Ovarian Cancers – Effects on Paclitaxel-Mediated Mitotic Catastrophe. Clin Cancer Res 2011; 17:6924-6933. [PubMed]

  • Kwan TT, Cheung AN, Lo SS, Lee PW, Tam KF, Chan KK, Ngan HY. Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. Acta Obstet Gynecol Scand. 2011 May;90(5):445-51. 

  • Kwan TT, Tam KF, Lee PW, Chan KK, Ngan HY. The effect of school-based cervical cancer education on perceptions towards human papillomavirus vaccination among Hong Kong Chinese adolescent girls. Patient Educ Couns. 2011 Jul;84(1):118-22.

  • Liu SS, Chan KY, Leung RC, Chan KK, Tam KF, Luk MH, Lo SS, Fong DY, Cheung AN, Lin ZQ, Ngan HY. Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women - a population-based study. PLoS One. 2011 May 3;6(5):e19244.

  • Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, Yao KM, Ngan HY. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One. 2011;6(8):e23790. [PubMed]

  • Mak VC, Lee L, Siu MK, Wong OG, Lu X, Ngan HY, Wong ES, Cheung AN. Downregulation of ASPP1 in gestational trophoblastic disease: correlation with hypermethylation, apoptotic activity and clinical outcome. Mod Pathol. 2011 Apr;24(4):522-32.

  • Ngan HY, Garland SM, Bhatla N, Pagliusi SR, Chan KK, Cheung AN, Chu TY, Domingo EJ, Qiao YL, Park JS, Tay EH, Supakarapongkul W. Asia oceania guidelines for the implementation of programs for cervical cancer prevention and control. J Cancer Epidemiol. 2011;2011:794861. 

  • Ngan HY. Preface. Uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):679. 

  • Tam KF, Cheung AN, Szeto E, Ngan HY. Atypical glandular cells diagnosed during pregnancy and the postpartum period: a retrospective analysis. Eur J Obstet Gynecol Reprod Biol. 2011 Apr;155(2):213-6.

  • Tse KY, Crawford R, Ngan HY. Staging of uterine sarcomas. Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):733-49. 

  • Zhang HJ, Siu MK, Yeung MC, Jiang LL, Mak VC, Ngan HY, Wong OG, Zhang H, Cheung AN. Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma. Carcinogenesis 2011; 32:765-71. [PubMed]

  • Zhang HJ, Siu MK, Yeung MC, Jiang LL, Mak VC, Ngan HY, Wong OG, Zhang HQ, Cheung AN. Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma. Carcinogenesis. 2011 May;32(5):765-71. 

  • Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, Wong OG, Wong ES, Chan HY, Cheung AN. Overexpression of dedicator of cytokinesis I (Dock180) in ovarian cancer correlated with aggressive phenotype and poor patient survival. Histopathology. 2011 Dec;59(6):1163-72. [PubMed]

  • Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, Wong OG, Wong ES, Chan HY, Cheung AN. Overexpression of Dock180 in ovarian cancer correlated with aggressive phenotype and poor patients’ survival. Histopathology 2011; 59: 1163-72. [PubMed]

2010

  • Cheung ANY, Tsun OKL, Ng KM, Szeto EF, Siu KY, Wong ESY, Ngan HYS. P634A4 and TAp73 immunocytochemistry in liquid-based cervical cytology—potential biomarkers for diagnosis and progress prediction of cervical neoplasia. Modern Pathology 2010;23:559-66. (Publication No. : 176804) 

  • Chow SN, Soon R, Park JS, Pancharoen C, Qiao YL, Basu P, Ngan HYS. Knowledge, attitudes, and communication around human papillomavirus (HPV) vaccinatin amongst urban Asian mothers and physicians. Vaccine 2010;28:3809-17. (Publication No. : 171555) 

  • Hu YJ, Ip PP, Chan KK, Tam KF, Ngan HY. Ovarian clear cell carcinoma with choriocarcinomatous differentiation: report of a rare and aggressive tumor. Int J Gynecol Pathol 2010;29:539-45.

  • Janda M, Gebski V, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, McCartney A, Nascimento M, Neesham D, Nicklin JL, Oehler MK, Otton G, Perrin L, Salfinger S, Hammond I, Leung Y, Walsh T, Sykes P, Ngan HYS, Garrett A, Laney M, Ng TY, Tam KF, Chan KKL, Wrede CDH, Pather S, Simcock B, Farrell R, Obermair A. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomized trial. Lancet Oncol. 2010;11:772-80. (Publication No. : 175333) 

  • Jiang L, Siu MK, Wong OG, Tam KF, Lam EW, Ngan HY, Le XF, Wong ES, Chan HY, Cheung AN. Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. Mol Cancer. 2010;9:318.

  • Kwan TT, Tam KF, Lee PW, Lo SS, Chan KK, Ngan HY. De-stigmatising human papillomavirus in the context of cervical cancer: a randomised controlled trial. Psychooncology 2010;19:1329-39.

  • Leung TH, Ngan HY. Interaction of TAp73 and breast cancer-associated gene 3 enhances the sensitivity of cervical cancer cells in response to irradiation-induced apoptosis. Cancer Res 2010;70:6486-96. [PubMed]

  • Liu S, Leung CY, Chan KKL, Cheung ANY, Ngan HYS. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay by comparison with Roche Linear Array HPV genotyping assay. Journal of Clinical Microbiology. 2010;48:758-64. (Publication No. : 176805) 

  • Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107-14.

  • Ngan HYS, Cheung ANY, Tam KF, Chan KKL, Tang HW, Bi D, Descamps D, Bock HL. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong, Hong Kong Med J 2010;16:171-9. (Publication No. : 170837) 

  • Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, Tsao SW, Strömblad S, Cheung AN. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A. 2010;107:18622-7.

  • Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, Tam KF, Ngan HY, Chan QK, ChanDC, ChanKY, Cheung AN. Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion. Int J Cancer. 2010 Jul 1;127(1):21-31.

  • SiuKY, Yeung CW, Zhang H, Kong SH, Ho WKJ, Ngan HYS, ChanDC, Cheung ANY. p21-activated kinase 1 promotes aggressive phenotype, cell proliferation and invasion in gestational trophoblastic disease. Am J Pathol 2010;176:3015-22. (Publication No. : 176674)

  • Suh DH, Kim JW, Aziz MF, Devi UK, Ngan HY, Nam JH, Kim SC, Kato T, Ryu HS, Fujii S, Lee YS, Kim JH, Kim TJ, Kim YT, Wang KL, Lee TS, Ushijima K, Shin SG, Chia YN, Wilailak S, Park SY, Katabuchi H, Kamura T, Kang SB. Asian society of gynecologic oncology workshop 2010. J Gynecol Oncol. 2010;21:137-50.

  • Wang Y, Chan DW, Liu VWS, Chiu PM, Ngan HYS. Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis, Clinical Cancer Research 2010;16:2529-39. [PubMed]

  • Zhang HJ, Siu MK, Jiang LL, Mak VC, Ngan HY, Cheung AN. Overexpression of the Parkinson disease protein DJ-1 and its regulator PTEN in gestational trophoblastic disease. Int J Gynecol Pathol. 2010;29:468-75.

2009

  • KY Tse, KKL Chan, KF Tam, Ngan HY. Gestational trophoblastic disease. Obstetrics, Gynaecology & Reproductive Medicine 2009; 19: 89 – 97

  • KY Tse, VW Liu, DW Chan, PM Chiu, KF Tam, KK Chan, XY Liao, Cheung AN, HY Ngan. Epigenetic alteration of the Metallothionein 1E gene in human endometrial carcinomas. Tumour Biol 2009; 30: 93 - 99

2008

  • Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK, Ngan HY. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis. 2008 Sep;29(9):1742-50.  [PubMed]

  • Chan DW, Yu SY, Chiu PM, Yao KM, Liu VW, Cheung AN, Ngan HY. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol. 2008 Jul;215(3):245-52. [PubMed]

  • Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol. 2008 Jan;111(1):144-51. [PubMed]

  • KK Chan, KF Tam, KY Tse, Ngan HY. The role of regular physical examination in the detection of ovarian cancer recurrence. Gynecol Oncol 2008; 110; 158 – 61

2006

  • Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW, Ngan HY. Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res. 2006 Jul 1;12(13):3922-7. [PubMed]

Research Grants

  • Roles of HPV-E6 protein and CD55(+) population in regulating radio-resistance in cervical cancer cells. University Grant Committee of Hong Kong (UGC) Research Grant Council (RGC) General Research Fund (GRF) 2013-2014 (Principal Investigator) HK$ 1,255,747 (2013-2016)
  • Functional characterization and clinical significance of DNp73-C35 in ovarian cancer. University Grant Committee of Hong Kong (UGC) Research Grant Council (RGC) General Research Fund (GRF) 2011-2012 (Principal Investigator) HK$ 1,092,500 (2011-2014)